retatrutide phase 3 results hits 28% weight loss in Lost 50lbs in 3 months!
Description
These powerful, clinically proven medications are helping thousands achieve meaningful, sustainable weight loss when paired with medical guidance
Meal-induced changes in extracellular 5-HT in medial hypothalamus of lean (Fa/Fa) and obese (fa/fa) Zucker rats
Eid RA, Bin-Meferij MM, El-Kott AF, et al
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising liver fat reduction in Phase 2 trials, but it does not yet hold UK marketing authorisation
This is recognised by 22-30% of respondents across different age groups
Gastrointestinal Effects Nausea, diarrhea, and constipation represent the most common side effects during Retatrutide use
